Global Pulmonary Embolism Market, By Symptoms (Shortness of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Others), Diagnosis (Chest X-Ray, ECG, MRI, CT Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Others), Treatment (Medications, Mechanical Devices, Surgery, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030.
Pulmonary Embolism Market Analysis and Size
In recent years, the global pulmonary embolism market is anticipated to grow rapidly during the forecast period 2023-2030. The global market for pulmonary embolism is primarily driven by an increase in the use of prevalence of pulmonary embolism diseases. In the elderly, pulmonary illnesses can be lethal. The rising prevalence of this health problem among the world's elderly population is expected to drive the global pulmonary embolism market's sales in the coming years. Different technological breakthroughs are being incorporated into the healthcare industry in terms of diagnostics, healthcare, and medical treatment. This scenario favours the expansion of the global pulmonary embolism market.
Data Bridge Market Research analyses that the global Pulmonary Embolism Market which was USD 1.65 billion in 2022, is expected to reach USD 3.12 billion by 2030, and is expected to undergo a CAGR of 8.30% during the forecast period 2023-2030. This indicates that the market value. “Chest Pain” dominates the Symptoms segment of the global pulmonary embolism market owing to rising prevalence of this heart problem among the world's elderly population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pulmonary Embolism Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Symptoms (Shortness of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Others), Diagnosis (Chest X-Ray, ECG, MRI, CT Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Others), Treatment (Medications, Mechanical Devices, Surgery, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Jerusalem), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Bristol-Myers Squibb Company (U.S.), Hikma Pharmaceuticals PLC (U.K.), Johnson & Johnson Private Limited (U.S.), Novartis AG (Switzerland), Boehringer Ingelheim International GmbH. (Germany), Fresenius Kabi AG (Germany), Bayer AG (Germany), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Baxter (U.S.), AstraZeneca (U.K.), Genentech Inc. (U.S.), Aspen Holdings (South Africa)
|
|
Market Opportunities
|
|
Market Definition
A pulmonary embolism is a blood clot in the lung that develops when a clot from another region of the body (usually the leg or arm) travels through the bloodstream and lodges in the lung's blood arteries. This reduces blood flow to the lungs, lowers oxygen levels in the lungs, and raises pulmonary artery blood pressure. PEs can cause heart or lung damage, as well as death, if not treated promptly.
Global Pulmonary Embolism Market Dynamics
Drivers
- Increasing Prevalence of Cancer
The global pulmonary embolism market is driven by an increase in prevalence of cancer. Patients who are receiving chemotherapy or who have a family history of the condition are at the greatest risk, which is expected to increase demand for the medications. The industry is expected to develop in response to the growing number of cancer patients. Cancer killed about 10 million people in 2020, according to the World Health Organization.
- Increasing Investment for Healthcare Infrastructure
Another significant factor influencing the growth rate of pulmonary embolism market is the rising healthcare expenditure which helps in improving its infrastructure.
- Rise in Smoking Addiction
Long-term smoking addiction is one of the leading causes of lung illnesses including pulmonary embolism. The stress levels of this population base have risen significantly as a result of growing urbanization, industrialization, and increased work pressure. This scenario is expected to result in an increase in smoking addiction, which would lead to greater sales potential in the worldwide global pulmonary embolism market.
Opportunity
- Increase in the Number of Research and Development Activities
Moreover, the market's growth is fuelled by an increase in the number of research and development activities. This will provide beneficial opportunities for the global pulmonary embolism market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the global pulmonary embolism market growth during the forecast period 2023-2030.
Restraint/Challenge
- Limited Awareness and Knowledge
There is a lack of awareness and knowledge about pulmonary embolism among healthcare professionals and the general population. This can result in delayed recognition of symptoms, leading to delays in seeking medical attention and appropriate treatment.
This global pulmonary embolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global pulmonary embolism market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In August 2021, Boston Scientific had announced the initiation of randomized controlled trial for the EkoSonic™ Endovascular System. In patients with PE and peripheral artery occlusions, the EKOS device employs ultrasound radiation in combination with a thrombolytic medication to break blood clots and restore blood flow. The EKOS system's ultrasound technology speeds up thrombolysis, or the breakup of a clot, reducing the time it takes to treat a patient and lowering the required thrombolytic dose, which can lead to better outcomes and a lower risk of bleeding.
Global Pulmonary Embolism Market Scope
The global pulmonary embolism market is segmented on the basis of symptoms, diagnosis, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Symptoms
- Shortness of Breath
- Chest Pain
- Cough
- Irregular Heartbeat
- Dizziness
- Fever
- Cyanosis
- Others
Diagnosis
- Chest X-Ray
- ECG
- MRI
- CT Scan
- Pulmonary Angiography
- Venography
- Venous Ultrasound
- D-Dimer Test
- Others
Treatment
- Medications
- Mechanical Devices
- Surgery
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Pulmonary Embolism Market Regional Analysis/Insights
The global pulmonary embolism market is analysed and market size insights and trends are provided by country, product, application, type and end-users as referenced above.
The countries covered in the global pulmonary embolism market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the global pulmonary embolism market because of the presence of major key players and growing prevalence of pulmonary embolism diseases in this region.
Asia-Pacific is expected to grow during the forecast period 2023-2030 due to rising number of geriatric people and increasing prevalence of pulmonary embolism in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
Global pulmonary embolism market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for global pulmonary embolism market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global pulmonary embolism market. The data is available for historic period 2015-2020.
Competitive Landscape and Global Pulmonary Embolism Market Share Analysis
The global pulmonary embolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pulmonary embolism market
Some of the major players operating in the global pulmonary embolism market are:
- Abbott (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Jerusalem)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Novartis AG (Switzerland)
- Boehringer Ingelheim International GmbH. (Germany)
- Fresenius Kabi AG (Germany)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Merck & Co., Inc. (U.S.)
- Baxter (U.S.)
- AstraZeneca (U.K.)
- Genentech Inc. (U.S.)
- Aspen Holdings (South Africa)
SKU-